Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lexapro for Self-harm in Borderline Personality Disorder
NCT01103180Phase 2Terminated
- Sponsor
- University of Chicago
- Start
- Sep 2010
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of escitalopram in borderline personality disorder (BPD), major depressive disorder (MDD), sponsored by University of Chicago. Started Sep 2010; status: terminated.
02
Drugs
escitalopram
03
Conditions
borderline personality disorder (BPD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01103180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01103180.